Blaner v. IDEC Pharmaceuticals Corp.

58 Pa. D. & C.4th 129, 2002 Pa. Dist. & Cnty. Dec. LEXIS 209
CourtPennsylvania Court of Common Pleas, Alleghany County
DecidedMarch 28, 2002
Docketno. GD00-21994
StatusPublished
Cited by1 cases

This text of 58 Pa. D. & C.4th 129 (Blaner v. IDEC Pharmaceuticals Corp.) is published on Counsel Stack Legal Research, covering Pennsylvania Court of Common Pleas, Alleghany County primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Blaner v. IDEC Pharmaceuticals Corp., 58 Pa. D. & C.4th 129, 2002 Pa. Dist. & Cnty. Dec. LEXIS 209 (Pa. Super. Ct. 2002).

Opinion

WETTICK JR., J.,

The subject of this opinion and order of court is a motion filed by defendant-manufacturers seeking a ruling that a physician whom the manufacturers retained (Grant Anhalt M.D.) may furnish expert testimony in these proceedings. Dr. Anhalt is a nationally recognized expert in the field of PNP.1 It is Dr. Anhalt’s practice to respond, with[131]*131out compensation, to inquiries of physicians located throughout the country treating patients who may be suffering from PNP. In the present case, a treating physician of plaintiff-husband, during the diagnosis and treatment of plaintiff, had two telephone conversations with Dr. Anhalt. It is the position of plaintiffs that Dr. Anhalt cannot offer expert testimony on behalf of the defendant-manufacturers in this litigation because of his involvement in plaintiff’s treatment.

According to the allegations in plaintiffs’ second amended complaint, plaintiff was being treated for chronic lymphocytic leukemia. On December 18, 1999, a physician (defendant Dr. Lim) administered the drug Rituxan. Plaintiff suffered an adverse and/or allergic reaction and developed a severe rash. On three additional occasions between November 24, 1999, and December 9,1999, the same physician administered additional doses of Rituxan and plaintiff suffered worsening adverse and/ or allergic reactions.

Between January and May 2000, plaintiff was seen by three physicians (defendants Miller, Ruschak, and Rao) for his skin rash. These physicians did not diagnose or treat plaintiff for PNP, the condition from which plaintiff was suffering. In July 2000, the condition was properly diagnosed by another doctor.

In this lawsuit, plaintiffs raise claims based on negligent medical care against treating physicians and a hospital, and claims against the manufacturing defendants (Genentech and IDEC Pharmaceuticals) based on allegations that Rituxan caused the PNP.2 In this lawsuit, [132]*132plaintiffs have not sued the physician who contacted Dr. Anhalt.

It is the position of Genentech and IDEC Pharmaceuticals that Rituxan did not cause plaintiff’s PNP. These defendants wish to offer Dr. Anhalt as an expert in support of this position. Dr. Anhalt will testify that plaintiff’s exposure to Rituxan is not the cause of the PNP because the development of an autoimmune disease is a slow process.

At his October 9, 2001 deposition, Dr. Anhalt offered the following testimony: He is a physician in the Dermatology Department of Johns Hopkins University, School of Medicine. He was the first author on the publication that initially identified PNP as a unique syndrome. He has authored between 50 and 75 articles relating to PNP. He has accumulated data on more than 150 cases over the last 11 years. He has the most experience in the world with this disease.

He is constantly contacted by physicians seeking assistance with patients who may have PNP. In the fall of 2000, he talked, on one or two occasions, to a treating physician from Pittsburgh with whom he had no relationship (Dr. Earle) about a patient with PNP. He advised the treating physician that the disease sounded like PNP and that the physician should send serum from the patient to Dr. Anhalt’s lab so the treating physician could confirm that it was PNP.3

The discussion between Dr. Anhalt and the Pittsburgh physician included treatment. Dr. Anhalt suggested the [133]*133current regimen that was used at that time, which was Prednisone, Cyclosporine, and Cytoxan/Oxytocin. (T. 18, 96.)

In late January 2001, Dr. Anhalt was hired by Genentech as a consultant. On January 29, 2001, Dr. Anhalt entered into a written agreement with Genentech to review all serious, skin-related adverse events suffered by patients taking Rituxan. On February 16, 2001, he initially met with Genentech officials at a site visit. He reviewed 20 cases identified by number; these were cases in which there were reports of significant skin reactions. The 20 cases included plaintiff’s case.

For these 20 cases, Dr. Anhalt was not provided with a name or other identifying data. Dr. Anhalt issued a report dated March 8, 2001, in which he concluded that patient MCN095644 suffered from PNP and that his condition was not drug-related. Plaintiff is patient MCN095644. Dr. Anhalt’s report states that PNP occurs “as a slowly evolving complex of symptoms” (D00102); that PNP occurs primarily in the presence of a known neoplasm (tumor) (D00101); and that PNP “is an inherent risk due to the underlying malignancy, not to any therapy applied” (D00104).

In his deposition, Dr. Anhalt stated that the common denominator in the 150 PNP cases he has considered in the past 11 years is that a malignancy has been present for a long time before the patient develops PNP. It is not plausible that a short exposure to a drug could induce an autoimmune disease. Autoimmunity is not something that happens with a short-term exposure to anything. (T. 27-29.) This testimony, that Rituxan could not have been a triggering mechanism for plaintiff’s PNP because of [134]*134the short time between the exposure and the manifestation of the PNP, is the subject of defendant-manufacturers’ motion.

While there are no Pennsylvania appellate court cases addressing the issue of whether a physician who voluntarily furnishes advice to a treating physician regarding the diagnosis and treatment of the treating physician’s patient should also be characterized as a treating physician, cases in other jurisdictions hold that there is no physician-patient relationship. In these other jurisdictions, the issue arises primarily in the medical malpractice context. In almost all cases, the courts dismiss medical malpractice actions against the physician who rendered assistance to the treating physician on the ground that the law does not impose a duty of care where a physician has not assumed responsibility for the care of the patient. These cases are relevant to the present motion because a court that is not imposing a duty of care would not impose duties of confidentiality or loyalty.4

Plaintiffs rely on Pa.R.C.P. 4003.6, governing discovery of treating physicians, and case law construing this rule in support of their position that Dr. Anhalt cannot testify as an expert for any parties whom plaintiffs have sued.

Rule 4003.6 reads as follows:

“Rule 4003.6. Discovery of treating physician
[135]*135“Information may be obtained from the treating physician of a party only upon written consent of that party or through a method of discovery authorized by this chapter. This rule shall not prevent an attorney from obtaining information from
“(1) the attorney’s client,
“(2) an employee of the attorney’s client, or
“(3) an ostensible employee of the attorney’s client.”

In Marek v. Ketyer, 733 A.2d 1268 (Pa. Super. 1999), the court ruled that a treating physician for the plaintiff may not testify as an expert for a defendant because of the privacy interest underlying the physician-patient relationship and the physician’s duty of loyalty to the patient.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Francis v. Northumberland County
636 F. Supp. 2d 368 (M.D. Pennsylvania, 2009)

Cite This Page — Counsel Stack

Bluebook (online)
58 Pa. D. & C.4th 129, 2002 Pa. Dist. & Cnty. Dec. LEXIS 209, Counsel Stack Legal Research, https://law.counselstack.com/opinion/blaner-v-idec-pharmaceuticals-corp-pactcomplallegh-2002.